Cannabis Law Report

APRIL 21, 2022

Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . 30,000 patient doses) of MDMA in a four-step process beginning with a non-controlled starting material. The safety and efficacy of MDMA-assisted therapy is currently under investigation.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

PrestoDoctor

FEBRUARY 6, 2023

The doctor must be registered with the Oklahoma Medical Marijuana program. Other states have a list of qualifying conditions that the patients must meet to get an MMJ. Finally, you will complete the application and get charged for your appointment (patients only pay if approved!). Your patient status remains confidential.

Marijuana 52

Marijuana Patients Conditions Access 52

Cannabis Law Report

JULY 9, 2021

Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. Right to Try laws permit patients with serious or life-threatening diseases to access drugs that do not yet have government approval.

Law 105

Law Therapy Clinical Trials Research and Development 105

PrestoDoctor

JANUARY 14, 2020

Who Monitors This Program in Oklahoma? The Oklahoma Medical Marijuana Authority (OMMA) manages the MMJ program for the State of Oklahoma. This agency oversees licensing, regulation, and administration of the program. Other states have a list of conditions that the patients must meet to get an MMJ. Will I Be Put on a List?

Marijuana 52

Marijuana Patients Conditions Programs 52

PrestoDoctor

JANUARY 14, 2020

Who Monitors This Program in Oklahoma? The Oklahoma Medical Marijuana Authority (OMMA) manages the MMJ program for the State of Oklahoma. This agency oversees licensing, regulation, and administration of the program. Other states have a list of conditions that the patients must meet to get an MMJ. Will I Be Put on a List?

Marijuana 52

Marijuana Patients Conditions Programs 52

CannaMD

SEPTEMBER 15, 2020

Current Florida medical marijuana patient? Patients suffering from cancer, epilepsy, chronic seizures, or muscle spasms could use low-THC cannabis products recommended by a licensed doctor. Doctors and patients had to register on the Compassionate Use Registry , an online database maintained by the Florida Department of Health.

Law 126

Law Marijuana Patients Treatment 126

Cannabis Law Report

JUNE 4, 2021

He practiced as a British Physiotherapist for over fifteen years, running clinics that specialized in integrative pain management and injury rehabilitation, treating over 40,000 patients. Based on the way it’s produced, Delta 8-THC should be batch tested to ensure consumer safety.

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

Canna Law Blog

SEPTEMBER 6, 2023

Many people in the cannabis industry are convinced that this HHS recommendation to the Drug Enforcement Administration (DEA) means that the DEA will undertake this rescheduling (and fairly quickly, too–which would be a huge departure from its refusal to reschedule back in 2016). Just my two cents; feel free to disagree.

Research and Development 114

Research and Development DEA Marijuana Pharmaceutical 114

CannaMD

SEPTEMBER 10, 2020

This creates a somewhat confusing landscape for mothers who might benefit from cannabis-based therapies, but are also concerned for the safety of their child and the very real possibility of institutional intervention when marijuana use during pregnancy is documented. But despite these revelations, both messaging and legalities have lagged.

Marijuana 59

Marijuana Therapy Data THC 59

Canna Law Blog

MAY 7, 2020

At the same time, because of the federal illegality of cannabis, the federal government has routinely denied third party requests for further research in regards to its potential medical benefits, among other health and safety impacts. As of December 2019, there are only two patients on the coveted list and no new entrants are permitted.

DEA 72

DEA Research and Development Cultivation Supply Chain 72

Cannabis Law Report

NOVEMBER 2, 2021

Testing for Safety: Are Impurities a Problem? Testing for Safety: Are Impurities a Problem? At present, with almost no regulation over the industry, there is a definite risk of what chemist and hemp safety expert Dr. Matthew Curran describes to Refinery29 as “kitchen chemistry.” Table of Contents. Executive Summary.

THC 96

THC CBD Legalization Vaping 96

Veriheal

JUNE 23, 2022

Outdated practices and a patchwork of laws create a legal minefield for medical patients to navigate in particular. A great example of this can be found in Pennsylvania with the case of medical cannabis patient Patrick Murphy. MMJ Patients Criminalized Despite Legality.

Consumption 104

Consumption Legalization Concentrates Patients 104

Cannabis Law Report

JULY 1, 2021

Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries. Things have changed a little in the past twenty years, when the DEA gave some researchers permission to study limited amounts of certain psychedelics. POPLAR will publish original law and policy research.

Law 105

Law Research and Development Therapy DEA 105

Cannabis Law Report

SEPTEMBER 23, 2019

Marijuana and related substance misuse are complex issues impacting family medicine, patient health, and public health. Barriers to facilitating both clinical and public health research regarding marijuana is detrimental to treating patients and the health of the public. Executive Summary. Relevant AAFP Policy. Call to Action.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Cannabis Law Report

APRIL 8, 2022

Later that year, Doblin sued the DEA for the first time. The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. submitted his first DEA application to manufacture marijuana for use in medical research.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

APRIL 13, 2022

market presence, complementary client programming and respected clinical research capabilities allow us to accelerate our strategic growth plans and broaden access to healing and wellness.” Increased client programming with complementary service offerings to be shared and expanded across the combined clinic network.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

The Cannigma

MAY 15, 2023

Ketamine has a long safety record as an anesthetic since the 1980s, and it has also been successfully used “off-label” for over a decade to treat conditions such as anxiety, depression, OCD, and PTSD, among others. Patients may want to seek assistance from a certified professional prior to embarking on treatment.

Therapy 78

Therapy Access Blood Pressure Treatment 78

Meadow

JULY 13, 2018

19:05) What equity programs are currently in place in each of your cities and why are they important to you and your city? (25:28) 25:28) Going beyond equity programs, have there been conversations about creating more diversity in the cannabis industry in your respective cities?

Wellness and Beauty 40

Wellness and Beauty Policy Consumption Cannabis 40

The Cannigma

SEPTEMBER 12, 2021

The safety of using these products however, is still unknown. Depending on the state you’re in, THC products may be legally accessible to any adult, and other states restrict access to medical patients only. Marijuana (defined in the US as any cannabis plant where THC>0.3%) is a schedule I drug according to the DEA and FDA.

THC 98

THC Research and Development Cannabinoids CBD 98

Canna Law Blog

NOVEMBER 16, 2021

The enforcement role moves from DEA to ATF. When it comes to enforcing federal cannabis regulations, the Drug Enforcement Administration (“DEA”) is out and the Bureau of Alcohol, Tobacco, Firearms, and Explosives (“ATF”) is in (in addition to TTB as the primary overseer). .

DEA 89

DEA Business Banking Food 89

SMPL

FEBRUARY 11, 2020

President Trump proposed ending an existing policy that protects state medical marijuana programs from Justice Department interference as part of his fiscal year 2021 budget plan released on Monday. Questions remain regarding the safety of these compounds,” it continued. markets outpace increases to Agency resources.”.

Research and Development 40

Research and Development Legalization Marijuana Programs 40

Cannabis Law Report

MARCH 25, 2019

The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. ii] See How to reschedule marijuana, and why it’s unlikely anytime soon , The Brookings Institution [2015].

Banking 45

Banking Law Marijuana State Laws 45

Cannabis Law Report

JULY 14, 2021

The proposed plan would also establish a regulatory framework for state-legal cannabis businesses, expunge non-violent cannabis convictions, and create programs to support small and minority-owned cannabis businesses while reinvesting resources in the communities that have been disproportionately harmed by prohibition. Ron Wyden, D-Ore.,

Legislation 71

Legislation Banking History Access 71